BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio4t2 Trials CAR-T for Solid Tumors Without Lymphodepletion

The PrismCore platform generates CAR-T that recognizes overexpressed self-antigens on solid tumors. Bio-Engine adapts the CAR-T to transiently recogni...

October 18, 2023 | News

CANbridge Reaches Full Enrollment in Phase 2 Trial for Gaucher Disease in China

Phase 2 is a randomized, double-blind, dose comparison study to evaluate the efficacy, safety and pharmacokinetics of CAN103 in newly treated GD patients, ...

October 17, 2023 | News

WuXi Biologics Introduces WuXiUI™: Enhancing Bioprocessing for Efficiency and Quality in Commercial Manufacturing

WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics d...

October 17, 2023 | News

Ascentage Pharma & AstraZeneca Collaborate on Phase III Study for CLL/SLL Treatment

The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's B...

October 16, 2023 | News

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

October 13, 2023 | News

MediLink and BioNTech Partner for Advanced Anti-Cancer Drug

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of ...

October 13, 2023 | News

Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing

Headquartered in Beijing, China, Sino Biological is the world’s leading provider of mammalian cell-based recombinant proteins, antibodies, and relate...

October 10, 2023 | News

Kexing Biopharm Hosts High-end Forum for China-MENA & South Asia Pharma Cooperation in Emerging Markets

MENA and South Asia are recognized as pivotal regions for Kexing Biopharm's overseas business expansion. The event brought together industry experts and he...

October 10, 2023 | News

CANbridge's CAN108 (LIVMARLI®) Receives Approval in Taiwan for ALGS-Related Pruritus

CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ...

October 09, 2023 | News

Innovent Initiates Phase 3 Study of Efdamrofusp Alfa for Age-related Macular Degeneration

nnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 09, 2023 | News

Nortech Systems Suzhou Facility Certified to Produce Class II Medical Devices for Asia Market

“NMPA certification is a major step forward for Nortech Systems and our customers in the region,” said Nortech Systems CEO, Jay D. Miller. &ldq...

October 05, 2023 | News

FDA Clears Transcenta for Global Phase III Trial of Osemitamab in Gastric Cancer

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

October 04, 2023 | News

WuXi Bio Applauds Amicus on FDA Approval for Pompe Disease Therapy

Pombiliti™, a recombinant human GAA enzyme (rhGAA) naturally expressed with high levels of bis-M6P (Mannose 6-Phosphate), was started at WuXi Biologi...

October 02, 2023 | News

Mabwell Starts Phase Ib/II Trial for Nectin-4 ADC with PD-1 Inhibitor

The clinical trial (CTR20232677) is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 9MW2821 in combination with ...

September 29, 2023 | News

Stay Connected